[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 17, 2007

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;297(3):261-263. doi:10.1001/jama.297.3.261-b

To the Editor: In their randomized trial of acute treatment of VTE, Dr Kearon and colleagues1 concluded that fixed-dose, unmonitored, subcutaneous unfractionated heparin is as effective and safe as fixed-dose, unmonitored, subcutaneous low-molecular-weight heparin. We are concerned about this conclusion.

First, studies have shown that the risk of recurrent VTE is higher among men than women; in some studies, the risk of recurrence was almost 4 times greater in men compared with women.2,3 In Kearon et al, the unfractionated heparin group had a greater proportion of female patients than did the low-molecular-weight heparin group (173 [49%] vs 147 [42%]). The authors did not adjust for the sex difference in their statistical analysis of efficacy. Sex-related difference in the risk of recurrence has to be taken into account in the interpretation of outcome events.

First Page Preview View Large
First page PDF preview
First page PDF preview
×